What is the official website of Hikma Pharmaceuticals ?

The official website of Hikma Pharmaceuticals is http://www.hikma.com.

What is Hikma Pharmaceuticals's cybersecurity risk score?

Hikma Pharmaceuticals has an AI-generated cybersecurity risk score of 767 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Hikma Pharmaceuticals experienced?

According to Rankiteo, Hikma Pharmaceuticals currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Hikma Pharmaceuticals been affected by any supply chain cyber incidents ?

According to Rankiteo, Hikma Pharmaceuticals has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Hikma Pharmaceuticals have SOC 2 Type 1 certification ?

According to Rankiteo, Hikma Pharmaceuticals is not certified under SOC 2 Type 1.

Does Hikma Pharmaceuticals have SOC 2 Type 2 certification ?

According to Rankiteo, Hikma Pharmaceuticals does not hold a SOC 2 Type 2 certification.

Does Hikma Pharmaceuticals comply with GDPR ?

According to Rankiteo, Hikma Pharmaceuticals is not listed as GDPR compliant.

Does Hikma Pharmaceuticals have PCI DSS certification ?

According to Rankiteo, Hikma Pharmaceuticals does not currently maintain PCI DSS compliance.

Does Hikma Pharmaceuticals comply with HIPAA ?

According to Rankiteo, Hikma Pharmaceuticals is not compliant with HIPAA regulations.

Does Hikma Pharmaceuticals have ISO 27001 certification ?

According to Rankiteo,Hikma Pharmaceuticals is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Hikma Pharmaceuticals operate in ?

Hikma Pharmaceuticals operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Hikma Pharmaceuticals have ?

Hikma Pharmaceuticals employs approximately 10,252 people worldwide.

Does Hikma Pharmaceuticals own any subsidiaries ?

Hikma Pharmaceuticals presently has no subsidiaries across any sectors.

How many LinkedIn followers does Hikma Pharmaceuticals have ?

Hikma Pharmaceuticals's official LinkedIn profile has approximately 637,630 followers.

What is the NAICS classification code for Hikma Pharmaceuticals ?

Hikma Pharmaceuticals is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Hikma Pharmaceuticals have a Crunchbase profile ?

Yes, Hikma Pharmaceuticals has an official profile on Crunchbase, which can be accessed here: https://www.crunchbase.com/organization/hikma-pharmaceuticals.

Does Hikma Pharmaceuticals have a LinkedIn profile ?

Yes, Hikma Pharmaceuticals maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/hikma-pharmaceuticals.

How many cybersecurity incidents has Hikma Pharmaceuticals experienced ?

As of August 1, 2026, Rankiteo reports that Hikma Pharmaceuticals has not experienced any cybersecurity incidents.

How many peer or competitor companies does Hikma Pharmaceuticals have ?

Hikma Pharmaceuticals has an estimated 5,720 peer or competitor companies worldwide.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Hikma Pharmaceuticals

Boost Score +25 with badge (5 left)

767

/1000

Fair

792

/1000

Fair

Hikma Pharmaceuticals Vendor Cyber Rating & Cyber Score

hikma.com

cb in

Add Your Compliance Badge

For almost 50 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 800* high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing plants, 3 R&D hubs and c9,500 employees worldwide. *As of December 2025 Subscribe to our channel on YouTube https://youtube.com/@hikmapharmaceuticals5668 For all product information and enquiries, please contact us at [email protected]

Hikma Pharmaceuticals A.I CyberSecurity Scoring

Scoring History

Hikma Pharmaceuticals

Hikma Pharmaceuticals CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

Hikma Pharmaceuticals Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Hikma Pharmaceuticals

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Hikma Pharmaceuticals in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Hikma Pharmaceuticals in 2026.

Incident Types Hikma Pharmaceuticals vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Hikma Pharmaceuticals in 2026.

Incident History - Hikma Pharmaceuticals (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Hikma Pharmaceuticals Subsidiaries

Parent Company

Hikma Pharmaceuticals

Pharmaceutical Manufacturing

Website: http://www.hikma.com

Company Size: 5,001-10,000 employees

No subsidiary data available for this company.

Loading…

Hikma Pharmaceuticals Similar Companies

MACLEODS PHARMACEUTICALS LTD.

macleodspharma.com

A vertically integrated, Global Pharmaceutical Company. Established in 1989, we are engaged in developing, manufacturing, and marketing a wide range of formulations across several major therapeutic areas including anti-infectives, cardiovascular, anti-diabetic, dermatology, and hormone treatment. We develop, manufacture, and globally distribute a broad range of pharmaceutical products across therapies in multiple dosage forms such as solid orals, liquid orals, topical formulations, injectables (Dry Powder) metered dose inhalers and dry powder inhalers. Our Vision To be a leading global pharmaceutical company by providing high quality, affordable and innovative therapeutic solutions for patients with diverse medical needs. Our Mission To contribute towards improving patients’ quality of life across the globe, by providing effective and accessible medicines.

Parexel

parexel.com

Parexel is a leading global clinical research organization (CRO) providing insights-driven Clinical and Consulting solutions to the world’s life sciences industry. Leveraging deep local knowledge and a global breadth of clinical, regulatory and therapeutic expertise, our 24,000+ professionals worldwide work in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind — broadening access and making clinical research a care option for anyone, anywhere. Our proven track record spans 40+ years and drives us forward, advancing clinical research in healthcare’s most complex areas while harnessing innovation to drive efficiencies across every phase of the clinical development process. Our insights-driven approach, proven delivery and trusted execution are accelerating the delivery of life-changing treatments to patients — With Heart.™ We continue to earn recognition industrywide, including the 2025 Scrip Award for “Best Contract Research Organization – Full-Service Provider,” 2024 Fierce Biotech CRO Award for "Innovative Approaches to Patient-Centric Research" and the 2024 and 2023 Society for Clinical Research Sites (SCRS) Eagle Award. Community Guidelines Because Parexel’s social media channels are open to the general public and employees, we are not responsible for views expressed other than our own. However, we do not tolerate posts that are: • Abusive, harassing or threatening to others. • Defamatory, offensive, obscene, vulgar or depicting violence. • Hateful targeting by race/ethnicity, age, color, creed, religion, gender, sexual preference or orientation, nationality or political beliefs. • Sexually explicit or pornographic. • Fraudulent, deceptive, libelous, misleading or unlawful. • Referencing criminal or illegal activity. • Spamming. We reserve the right to remove comments that do not adhere to our guidelines and report users who violate the rules of our page.

Dr. Reddy's Laboratories

drreddys.com

Established in 1984, we are a global pharmaceutical company headquartered in Hyderabad, India. Driven by our purpose of ‘Good Health Can’t Wait’, we work to provide access to affordable and innovative medicines. We offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major markets include USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in future growth drivers such as access to novel molecules, digital therapeutics and consumer healthcare. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com. Caution Notice: Dr. Reddy's has been made aware of candidates receiving fraudulent job opportunities from unauthorised recruiting agencies or people impersonating Dr. Reddy's leaders. These fraudulent jobs may be advertised on employment sites or mimic our careers site and company email addresses. Please know that Dr. Reddy's Laboratories has no affiliation or connection to these situations. Dr. Reddy's (and its associated/group companies) follows a formal recruitment process through its own HR department. Please report immediately in case you suspect a fraudulent job. You may raise your concern by: Accessing https://drreddys.ethicspoint.com. Calling on the hotline number. List of hotline numbers are available in https://drreddys.ethicspoint.com. The hotline is available 24x7 in multiple languages. Writing to [email protected] or [email protected]. For our community guidelines on LinkedIn, please visit: https://shorturl.at/LTvNZ

SUN PHARMA

sunpharma.com

Sun Pharma is the world's fourth-largest speciality generic pharmaceutical company and No. 1 in India. We provide high-quality, affordable medicines trusted by customers and patients in over 100 countries. Sun Pharma's global presence is supported by more than 40 manufacturing facilities spread across 5 continents, R&D centres across the globe, and a multicultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities comprising around 3,000 scientists and R&D investments of over 6-8% of annual revenues. At Sun, our people are our greatest asset. Ours has never been a story of individual brilliance but of cultivating a culture of realising collective potential. In our journey, everyone is enabled to take charge in an environment that offers limitless growth opportunities. We are with you every step of the way, so you can shine for years to come. With the launch of our Employee Value Proposition (EVP), we define our promise to ‘Create Your Own Sunshine'—driven by the three pillars of Better Every Day, Take Charge, and Thrive Together. These pillars drive progress at Sun so that people can achieve what they would have thought impossible. Learn more about our EVP here: https://sunpharma.com/careers/

Merck Group

merckgroup.com

This channel is not intended for U.S. and Canadian visitors. Merck operates in the U.S. and Canada as EMD Serono in Healthcare, MilliporeSigma in Life Science and EMD Electronics in Electronics. An unaffiliated and unrelated company, Merck & Co., Inc., Kenilworth, NJ, US holds the rights in the trademark MERCK in the U.S. and Canada. _______________________________ We are Merck, a leading global science and technology company headquartered in Germany. We are curious explorers, courageous pioneers, and ingenious inventors. Our colleagues across the globe love innovating with science and technology to enrich people’s lives with our solutions in Life Science, Healthcare, and Electronics. Together, we dream big and are passionate about caring for our rich mix of people, customers, patients, and the planet. We believe in the positive power of science and technology. It has determined our actions since 1668 and inspires us to continue researching for a future worth living. As a family-owned company with over 350 years of experience, we stand for sustainability, responsibility, and innovative strength. We take pride in being a diverse and inclusive company that values and fosters the talents and abilities of our employees. That's why we are always looking for curious minds that see themselves imagining the unimaginable with us. Work your Magic and join Merck. Legal Disclaimer: www.merckgroup.com/en/legal-disclaimer.html Data Privacy Declaration: www.merckgroup.com/en/privacy-statement

Bristol Myers Squibb

cb bms.com

At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome. Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients. Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do. Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html

MSD

msd.com

At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.msd.com and connect with us on Facebook, Instagram, Twitter, and YouTube.

Novo Nordisk

cb novonordisk.com

We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Founded in Denmark in 1923, today we employ more than 68,800 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases. Want to learn more? Visit www.novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to block and remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html

Takeda

cb takeda.com

We strive to transform lives. While the science we advance is constantly evolving, our core purpose is enduring. For more than two centuries, our values have guided us to do what’s right for patients and for society. We know that changing lives requires us to do things differently. We start by listening to and addressing what really matters to patients, the people who love them, and those in the healthcare system who provide care. And that’s what inspires us all to be bold, push boundaries and set new standards that open up greater opportunities. Read our community guidelines: https://takeda.info/communityguidelines

Loading…

NEWS

Hikma Pharmaceuticals CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

March 05, 2026 08:00 AM

How The Hikma Pharmaceuticals (LSE:HIK) Investment Story Is Shifting As Analyst Views Diverge

Hikma Pharmaceuticals is back in focus after its fair value estimate was trimmed from £21.82 to £20.47. This shift has put fresh attention...

Read Article

February 26, 2026 08:00 AM

Hikma Pharma's gloomy outlook kicks shares to more than three-year low

British generic drugmaker Hikma Pharmaceuticals scrapped its medium-term targets as it forecast slower annual revenue growth and profit on...

Read Article

February 06, 2026 08:00 AM

What Analysts Think Is Changing The Story For Hikma Pharmaceuticals (LSE:HIK)

The latest update on Hikma Pharmaceuticals focuses on the price target, with the modelled fair value held at 22.14 while core assumptions...

Read Article

January 08, 2026 08:00 AM

Looking At The Narrative For Hikma Pharmaceuticals LSE HIK After Analyst Split On Fair Value

Hikma Pharmaceuticals' fair value estimate has been nudged down from £22.66 to £22.00 per share, a small adjustment that better reflects the...

Read Article

December 16, 2025 08:00 AM

The Character of the Corporation 2025: Navigating Tumultuous Times for Multinational Businesses

Directors Nina Henderson and John Zangardi on the key differences between serving on multinational and domestic boards.

Read Article

December 15, 2025 08:00 AM

How the Narrative Around Hikma Pharmaceuticals Is Shifting After Recent Analyst Target Moves

Hikma Pharmaceuticals' latest valuation update points to a slightly lower fair value estimate of about $22.66 per share, even as analysts...

Read Article

November 28, 2025 08:00 AM

How Recent Developments Are Shaping the Hikma Pharmaceuticals Story and Its Valuation

Hikma Pharmaceuticals' consensus analyst price target has seen a slight dip, moving from £23.55 to £23.36 per share.

Read Article

November 13, 2025 08:00 AM

Why The Narrative Around Hikma Pharmaceuticals Is Shifting After Recent Analyst Updates

Hikma Pharmaceuticals has recently seen its fair value estimate reduced from £25.40 to £23.55, as analysts update their assessments in light...

Read Article

September 19, 2025 07:00 AM

Hikma Pharmaceuticals PLC (LON:HIK) is favoured by institutional owners who hold 59% of the company

Key Insights Institutions' substantial holdings in Hikma Pharmaceuticals implies that they have significant influence...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-9044

SUMMARY

An OS command injection vulnerability exists in the VPN module of TP-Link AXE75 V1 routers. This vulnerability allows an adjacent, authenticated attacker to execute arbitrary commands on the device by importing a specially crafted VPN client configuration file. The issue arises from improper filtering of special characters. Successful exploitation of this vulnerability may enable an attacker to gain full control of the affected device, potentially compromising configuration integrity, network security, and service availability.

Published

Date2026-07-31

Updated

Date2026-07-31

RISK INFORMATION (Score: )

cvss4

Base Score: 8.5

Complexity: LOW

CVSS:4.0/AV:A/AC:L/AT:N/PR:H/UI:N/VC:H/VI:H/VA:H/SC:L/SI:L/SA:L/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-54909

SUMMARY

pion/stun is a Go implementation of STUN. Prior to 3.1.3, XORMappedAddress.GetFromAs can panic while parsing a malformed short XOR-MAPPED-ADDRESS attribute in STUN or ICE Binding-response parsing paths, allowing remote denial of service. This issue is fixed in version 3.1.3.

Published

Date2026-07-31

Updated

Date2026-07-31

RISK INFORMATION (Score: 5.3)

cvss3

Base Score: 5.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:L

Impact Score

1.4

Exploitability

3.9

REFERENCES

CVE-2026-54785

SUMMARY

gemini-bridge is a lightweight MCP server bridging AI agents to Google's Gemini AI via the official CLI. From 1.0.0 until 1.3.1, consult_gemini_with_files in inline mode read any file path supplied in the files argument without confining it to the working directory, then forwarded the contents to the Gemini CLI. Because the caller also controls query, the file contents are echoed back through the Gemini round-trip (and sent to Google), making this an arbitrary local file read. This issue is fixed in version 1.3.1.

Published

Date2026-07-31

Updated

Date2026-07-31

RISK INFORMATION (Score: 6.2)

cvss3

Base Score: 6.2

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:N/UI:N/S:U/C:H/I:N/A:N

Impact Score

3.6

Exploitability

2.5

REFERENCES

CVE-2026-54768

SUMMARY

WPGraphQL provides a GraphQL API for WordPress sites. From 2.0.0 until 2.15.1, the deprecated user field on SendPasswordResetEmailPayload lets an unauthenticated caller distinguish existing author-class accounts through the sendPasswordResetEmail mutation and obtain public profile fields. This issue is fixed in version 2.15.1.

Published

Date2026-07-31

Updated

Date2026-07-31

RISK INFORMATION (Score: )

cvss4

Base Score: 6.9

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:N/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-53573

SUMMARY

GeoNetwork is a catalog application to manage spatially referenced resources. From 3.12.0 until 4.2.16 and 4.4.11, unsafe redirect validation in GeonetworkOAuth2LoginAuthenticationFilter and KeycloakAuthenticationProcessingFilter permits an attacker-controlled external redirect after login. This issue is fixed in versions 4.2.16 and 4.4.11.

Published

Date2026-07-31

Updated

Date2026-07-31

RISK INFORMATION (Score: )

cvss4

Base Score: 4.8

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:A/VC:N/VI:N/VA:N/SC:N/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…